Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Protein dynamics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Protein dynamics. Displaying page 1 of 1.
    EudraCT Number: 2014-001182-27 Sponsor Protocol Number: CRFB002ADE27 Start Date*: 2014-08-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until stu...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004824-19 Sponsor Protocol Number: ML21206 Start Date*: 2008-08-08
    Sponsor Name:Roche Austria GmbH
    Full Title: Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study
    Medical condition: Chronic Lymphocytic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000105-65 Sponsor Protocol Number: 1 Start Date*: 2006-08-30
    Sponsor Name:Medical University of Vienna, Department of Internal Med. I, Division of Infectious Diseases
    Full Title: Comparative study of the efficacy and tolerance of intravenously administered azithromycin (1.5 g) given either as a single dose or over a 3 day period in patients with community-acquired pneumonia
    Medical condition: community aquired pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005101-21 Sponsor Protocol Number: GR-OG-279239-01 Start Date*: 2014-12-22
    Sponsor Name:Genera Research Ltd
    Full Title: Safety, tolerability, systemic pharmacokinetics and efficacy of a single dose of Osteogrow (rhBMP6 in autologous Whole Blood Coagulum Derived [WBCD] carrier) delivered locally to the fracture site ...
    Medical condition: Distal radius fracture.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10048049 Wrist fracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001691-21 Sponsor Protocol Number: GR-OG-279239-02 Start Date*: 2016-05-17
    Sponsor Name:Genera Research Ltd
    Full Title: SAFETY, TOLERABILITY, rhBMP6 PHARMACOKINETICS AND BONE HEALING EFFECT OF A SINGLE DOSE OF OSTEOGROW (rhBMP6 IN AUTOLOGOUS WHOLE BLOOD COAGULUM DERIVED [WBCD] CARRIER) IN ADULT PATIENTS TREATED BY H...
    Medical condition: Osteoarthritis of the medial knee joint compartment and/or symptomatic varus deformity.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10031300 Osteotomy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000797-30 Sponsor Protocol Number: SPI-IIT-002 Start Date*: 2013-10-08
    Sponsor Name:Department of Medical Research, Odense University Hospital, Svendborg Hospital
    Full Title: Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation
    Medical condition: Paroxysmal and persistent atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10071667 Persistent atrial fibrillation LLT
    18.1 100000004849 10066664 Recurrent symptomatic atrial fibrillation LLT
    18.1 100000004849 10003661 Atrial fibrillation paroxysmal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-000485-29 Sponsor Protocol Number: STH19752 Start Date*: 2017-05-23
    Sponsor Name:Dr
    Full Title: Prolonged ENoxapariN in primarY Percutaneous Coronary Intervention; a Pilot Pharmacodynamic study (PENNY PCI study)
    Medical condition: ST elevation myocardial infarction.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001639-35 Sponsor Protocol Number: CRFB002DDE25 Start Date*: 2014-08-11
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until stu...
    Medical condition: Visual impairment due to diabetic macula edema
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002938-20 Sponsor Protocol Number: AIO-STO-0218 Start Date*: 2019-03-27
    Sponsor Name:Charite - Universitätsmedizin Berlin
    Full Title: Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO
    Medical condition: metastatic gastro-oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000641-33 Sponsor Protocol Number: PAX Start Date*: 2022-04-21
    Sponsor Name:Fundació FLS de Lluita contra la Sida, les Malalties Infeccioses i la Promoció de la Salut i La Ciència
    Full Title: Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study
    Medical condition: Post-Acute-Covid-19 Syndrome
    Disease: Version SOC Term Classification Code Term Level
    24.0 10021881 - Infections and infestations 10085503 Post-acute COVID-19 syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-003374-40 Sponsor Protocol Number: 1-2016 Start Date*: 2016-11-29
    Sponsor Name:University of Tartu
    Full Title: The effects of augmented renal clearance on the pharmacokinetic/pharmacodynamic profile of piperacillin/tazobactam in children and young adults with malignant or non-malignant haematological or onc...
    Medical condition: The state of renal hyperfiltration during infection in children and young adults with malignant or non-malignant haematological or oncological diagnosis
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000456-26 Sponsor Protocol Number: Tumorspheres_Colrec Start Date*: 2017-07-10
    Sponsor Name:Vejle Hospital
    Full Title: Predictive value of in-vitro testing anti-cancer therapy sensitivity on tumorspheres from patients with metastatic colorectal cancer
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002876-26 Sponsor Protocol Number: 2017-002876-26 Start Date*: 2018-10-19
    Sponsor Name:South Tees Hospitals NHS Foundation Trust
    Full Title: Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome: a double-blind, phase II, pilot randomised controlled trial (TACTIC)
    Medical condition: Immunosenescence in patients who have had an acute coronary syndrome diagnosed within the last 6 months.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10011968 Decreased immune responsiveness PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000254-21 Sponsor Protocol Number: MO39839 Start Date*: 2021-04-20
    Sponsor Name:University Hospital Essen
    Full Title: Window of opportunity study of preoperative immunotherapy with atezolizumab (Tecentriq®) with or without tocilizumab (Actemra®) in local head and neck squamous cell carcinoma
    Medical condition: local squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003227-37 Sponsor Protocol Number: MK-3682-041 Start Date*: 2017-01-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 weeks of the Combination Regimen of MK-3682 + Ruzasvir in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3,...
    Medical condition: Treatment of chronic hepatitis C virus (HCV) infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002090-21 Sponsor Protocol Number: DEDALO Start Date*: 2019-05-16
    Sponsor Name:Fondazione EMN Italy Onlus
    Full Title: Daratumumab, pomalidomide and dexamethasone for del(17p) positive relapsed and relapsed/refractory multiple myeloma patients [DEDALO]
    Medical condition: Multiple Myeloma patients with relapsed or relapsed/refractory disease with the presence of del(17p) in the plasma cell clone
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003391-13 Sponsor Protocol Number: D3250C00059 Start Date*: 2019-09-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asth...
    Medical condition: Severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002654-21 Sponsor Protocol Number: RHMCAN1219 Start Date*: 2017-11-23
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY.
    Medical condition: Diffuse large B-cell lymphoma (most common type of non-Hodgkins lymphoma)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-001269-18 Sponsor Protocol Number: D-IVa/D-IVb Start Date*: 2013-12-19
    Sponsor Name:Universitätsklinikum Ulm (AöR)
    Full Title: A multicenter phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs).
    Medical condition: Everolimus/ribociclib cohort (D-IVa): Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and ind...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000072-42 Sponsor Protocol Number: RG_11-087 Start Date*: 2013-02-06
    Sponsor Name:The University of Birmingham
    Full Title: A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029261 Neuroblastoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DK (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Completed) AT (Completed) DE (Prematurely Ended) BE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 21:41:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA